Topics:
Melanoma/Skin Cancer • Medical Oncology
What scenario would flipped dosing versus standard dosing of Ipilimumab+Nivolumab be beneficial in metastatic melanoma?
CheckMate 511 trial showed reduced toxicity with flipped dosing of Ipilimumab+Nivolumab with similar progression free survival.
Answer from: Medical Oncologist at Academic Institution
Based on the CheckMate 511 study, the flipped dosing (ipi1/nivo3) demonstrated reduced high-grade (grade 3+) toxicities compared to the standard dose (ipi3/nivo1) [33.9% vs 48.3%, respectively]. In advanced melanoma patients who would benefit from combination ipi/nivo, I preferentially use the flipp...
Sign in or Register to read more